Lifecore Biomedical, Inc. (NASDAQ:LFCR) Major Shareholder Aron R. English Sells 15,847 Shares

Lifecore Biomedical, Inc. (NASDAQ:LFCR) major shareholder Aron R. English sold 15,847 shares of the company’s stock in a transaction dated Wednesday, May 7th. The shares were sold at an average price of $7.01, for a total transaction of $111,087.47. Following the transaction, the insider now directly owns 1,714,070 shares of the company’s stock, valued at approximately $12,015,630.70. This represents a 0.92 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Lifecore Biomedical Price Performance

LFCR stock opened at $7.00 on Thursday. The stock has a 50-day moving average price of $6.36 and a two-hundred day moving average price of $6.47. The company has a market cap of $258.99 million, a PE ratio of -12.49 and a beta of 0.65. The company has a current ratio of 2.32, a quick ratio of 1.21 and a debt-to-equity ratio of 9.21. Lifecore Biomedical, Inc. has a 12-month low of $3.68 and a 12-month high of $7.99.

Lifecore Biomedical (NASDAQ:LFCR) last announced its quarterly earnings results on Thursday, April 3rd. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The company had revenue of $35.15 million during the quarter, compared to analyst estimates of $33.23 million. Lifecore Biomedical had a negative net margin of 12.52% and a negative return on equity of 315.23%. As a group, research analysts predict that Lifecore Biomedical, Inc. will post -0.91 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in LFCR. Jane Street Group LLC lifted its stake in shares of Lifecore Biomedical by 101.7% in the third quarter. Jane Street Group LLC now owns 36,246 shares of the company’s stock worth $179,000 after acquiring an additional 18,277 shares in the last quarter. Barclays PLC boosted its holdings in Lifecore Biomedical by 301.7% in the third quarter. Barclays PLC now owns 29,944 shares of the company’s stock worth $147,000 after purchasing an additional 22,489 shares during the period. Geode Capital Management LLC lifted its position in shares of Lifecore Biomedical by 10.3% in the 3rd quarter. Geode Capital Management LLC now owns 597,685 shares of the company’s stock worth $2,948,000 after buying an additional 55,703 shares during the last quarter. MassMutual Private Wealth & Trust FSB bought a new position in Lifecore Biomedical in the fourth quarter worth about $209,000. Finally, ARS Investment Partners LLC acquired a new stake in Lifecore Biomedical in the fourth quarter worth $74,000. 83.36% of the stock is currently owned by hedge funds and other institutional investors.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.